Diflunisal 是一种水杨酸盐衍生物，是环氧合酶的抑制剂，具有非甾体抗炎和尿酸舒缓性能，可单独用作止痛剂和类风湿关节炎患者。

Diflunisal is a cyclooxygenase (COX) Inhibitor, used as an anti-inflammatory analgesic.

Diflunisal, an FDA-approved drug containing a salicylic acid substructure, inhibited CBP/p300 more potently than salicylate. Diflunisal exhibits anti-tumor activity against a specific leukemia carrying a t(8;21) translocation, a tumor previously reported to be dependent on p300 in vitro and in vivo[2].

Diflunisal-mediated kinetic stabilization of TTR(Rate-limiting transthyretin) should ameliorate TTR amyloidoses, provided that the nonsteroidal anti-inflammatory drug liabilities can be managed clinically[3].

HEK293T cells are transfected with expression vectors for WT p300 or catalitycally inactive mutant. 24 hr after transfection, cells are treated with diflunisal as indicated for 24 hr. H2B acetylation is measured by Western Blot using specified antibodies. Experiments are repeated four times. (Only for Reference)

22494-42-4

C13H8F2O3

250.201

二氟尼柳;MK-647;Fluniget;Dolobis;Dolobid;Flovacil

Ethanol:20 mg/mL (79.94 mM)
DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years